| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035099 That are antagonists of the progesterone receptor, in a female contraceptive kit |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | CA2422828A1 Novel tumor-associated marker |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422068A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/21/2002 | CA2391162A1 Novel topical oestroprogestational compositions with systemic effect |
| 03/20/2002 | EP1188768A2 LHRH antagonist peptides |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187846A2 11beta long-chain substituted estratrienes, method for their production, pharmaceutical preparations containing said 11beta long-chain substituted estratrienes, and their use for producing medicaments |
| 03/20/2002 | EP1187639A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| 03/20/2002 | EP1187618A1 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
| 03/20/2002 | CN1341122A Covalently bridged insulin dimers |
| 03/20/2002 | CN1081042C Traditional Chinese medicinal composition for stopping drug taking and preparation process thereof |
| 03/19/2002 | US6358951 Administering pyrazolo(4,3-c)pyridine derivative to treat obesity, congestive heart failure, osteoporosis, aging, bone and muscular disorders |
| 03/19/2002 | US6358947 Tetracyclic progesterone receptor modulator compounds and methods |
| 03/19/2002 | US6358706 Nucleotide sequences coding membrane protein; for use in treatment of epilepsy, schizophrenia, depression, sleep, stress, muscle, endocrine, respiratory, fertility, contraceptive, cardiovascular disorders and atherosclerosis |
| 03/19/2002 | US6358513 Local administration of a therapeutically effective amount of a botulinum toxin to a patient, thereby increasing secretion of thyroid hormone, and ameliorating severity of hashimoto's thyroiditis for between two months to six months |
| 03/19/2002 | CA2236673C (-)cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate |
| 03/14/2002 | WO2002020553A1 NOVEL POLYMORPHIC FORM OF 17-β-(N-TER.BUTYL CARBAMOYL)-4-AZA-5-α-ANDROST-1-EN-3-ONE AND A PROCESS FOR PREPARING IT |
| 03/14/2002 | WO2002020526A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | WO2002020519A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | WO2002020518A1 Thiazolidinone nitrate salt |
| 03/14/2002 | WO2002020090A2 Pharmaceutical compositions |
| 03/14/2002 | WO2002020031A2 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses |
| 03/14/2002 | WO2002020020A1 Exemestane as chemopreventing agent |
| 03/14/2002 | WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 03/14/2002 | WO2001062774A3 Purified lh |
| 03/14/2002 | WO2001060396A3 Method for treating thyroid disorders |
| 03/14/2002 | WO2001055392A3 Nuclear hormone receptors |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001049264A3 Pharmaceutical compositions for oral administration |
| 03/14/2002 | WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2001022982A3 Compositions for reducing sympathomimetic-induced side effects by serenoa repens extract |
| 03/14/2002 | WO2001021194A3 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032211 Novel dihydronaphthalene compounds and processes of producing the same |
| 03/14/2002 | US20020032196 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032181 For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated |
| 03/14/2002 | US20020031529 Neurotoxin therapy for diabetes |
| 03/14/2002 | US20020031528 Vaccines containing beta-hexosamine bind with antibodies and carriers |
| 03/14/2002 | CA2422159A1 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it |
| 03/14/2002 | CA2421506A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | CA2419590A1 Exemestane as chemopreventing agent |
| 03/13/2002 | EP1186672A2 Polymorphisms in the human organic anion transporter C (OATP-C) gene |
| 03/13/2002 | EP1186295A1 Pharmaceutical preparations containing extracts of soy isoflavone and probiotic micro-organisms |
| 03/13/2002 | EP1185694A1 49 human secreted proteins |
| 03/13/2002 | EP1185558A1 Peptide having preptin functionality |
| 03/13/2002 | EP1185543A1 50 human secreted proteins |
| 03/13/2002 | EP1185539A1 Organosilyl compounds having nuclear hormone receptor modulating activity |
| 03/13/2002 | EP1185304A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 03/13/2002 | EP1185302A2 Specifically targeted catalytic antagonists and uses thereof |
| 03/13/2002 | EP1185284A1 47 human secreted proteins |
| 03/13/2002 | EP1185246A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
| 03/13/2002 | EP0802910B1 Estrogen agonists/antagonists |
| 03/13/2002 | CN1340056A Steroides sulfatase inhibitors and methods for making and using same |
| 03/13/2002 | CN1340044A Nervinolin derivatives |
| 03/13/2002 | CN1339962A Stable non-aqueous single phase viscons vehicles and formulations utilizing such vehicles |
| 03/13/2002 | CN1339955A Gels formed by the interaction of poly(aldehyde) with various sabstances |
| 03/13/2002 | CN1080575C Conjugation-stablized polypeptide compositions, therapeutic delivery and disgnostic formulations comprising same, and method of making and using the same |
| 03/12/2002 | US6355648 Thio-oxindole derivatives |
| 03/12/2002 | US6355632 Naphthyl compounds, intermediates, compositions, and methods |
| 03/12/2002 | US6355483 Antisense nucleotides for use in the treatment of leukemia |
| 03/12/2002 | US6355241 In vivo production and delivery of erythropoietin |
| 03/11/2002 | CA2356466A1 Pharmaceutical preparations containing soy isoflavone extracts and probiotic micro-organisms |
| 03/07/2002 | WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017946A1 Bioactive fraction of eurycoma longifolia |
| 03/07/2002 | WO2002017944A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | WO2002017943A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | WO2002017942A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | WO2002017941A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | WO2002017940A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | WO2002017938A1 Use of extracts of the cassia alata plant |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017926A1 Pharmaceutical composition and method for treating hypogonadism |
| 03/07/2002 | WO2002017918A2 Sustained release formulations for growth hormone secretagogues |
| 03/07/2002 | WO2002017881A2 Transdermal pharmaceutical delivery composition |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001028591A3 Injection vehicle for polymer-based formulations |
| 03/07/2002 | US20020028838 E.g., 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7 hexahydro-pyrazolo-(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide; mobility impairments, e.g. identified by balance and gait, in the elderly |
| 03/07/2002 | US20020028790 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity |
| 03/07/2002 | US20020028762 Medicament and method for treating renal disease |
| 03/07/2002 | US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2424146A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | CA2424026A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | CA2424011A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |